MAPT and Alzheimer disease: Given that tau pathology correlates more closely with signs of neurodegeneration and clinical symptomatology, it is postulated that successful targeting of tau may be more effective in symptomatic AD; however, most preclinical data on tau therapies shows modest signs of efficacy when the therapy is initiated prior to pathology or when minimal pathology is present.